{"id":"W6908355009","doi":"10.26190/unsworks/27739","title":"Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c < 7%: Results From the CREDENCE Trial","year":2019,"lang":"en","type":"article","venue":"UNSWorks (University of New South Wales, Sydney, Australia)","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Akebia Therapeutics; HLS Therapeutics; Servier; Relypsa; Astellas Pharma; Novo Nordisk; NxStage; Innovent Biologics; Amarin Corporation; Alnylam Pharmaceuticals; Janssen Pharmaceuticals; Gilead Sciences; Daiichi Sankyo Europe; Kowa Company; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Ironwood Pharmaceuticals, Incorporated","keywords":"Canagliflozin; Type 2 diabetes; Kidney disease; Credence; Diabetes mellitus; Baseline (sea); Type 2 Diabetes Mellitus","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001405507,0.0007202884,0.001841329,0.0003408847,0.000251,0.001156553,0.0004573475,0.001047741,0.003303651],"category_scores_gemma":[0.00216836,0.0002979244,0.001891784,0.000400285,0.0006872225,0.001106031,0.0003687917,0.002092024,0.0005133394],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005229384,"about_ca_system_score_gemma":0.000550846,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00179617,"about_ca_topic_score_gemma":0.004195885,"domain_scores_codex":[0.9996334,0.0001579719,0.00002353699,0.00004978174,0.00005883589,0.0000763431],"domain_scores_gemma":[0.9993156,0.0002125054,0.0001513439,0.00008034888,0.00003391049,0.000206335],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8998592,0.006028226,0.01029009,0.001144082,0.003852243,0.000143162,0.00009302377,0.0008164633,0.001147193,0.0003881989,0.00694531,0.06929281],"study_design_scores_gemma":[0.876072,0.0469803,0.06532726,0.0002194048,0.004352587,0.0001938219,0.0001423568,0.001515534,0.0003828174,0.0008265912,0.003930519,0.00005667662],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9766039,0.01096622,0.0002116085,0.001940596,0.0007280143,0.0002521221,0.0008748707,0.0001063139,0.008316341],"genre_scores_gemma":[0.9901065,0.003425522,0.0003363003,0.001790505,0.0007471559,0.0001402037,0.001160298,0.00001157816,0.002281978],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003303651,"threshold_uncertainty_score":0.01105177,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02758369359214911,"score_gpt":0.2229293996957503,"score_spread":0.1953457061036012,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}